GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) announced that multiple innovative combination therapies of its oral pan‑RAS inhibitor GFH276 have received Clinical Trial Authorizations (CTA) from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), or completed clinical trial notifications with the Therapeutic Goods Administration (TGA) of Australia — with related studies spanning first‑line and subsequent‑line treatments for multiple major indications of RAS‑mutant solid tumors and some trials already enrolling patients across multiple dose levels.
Regulatory Milestone
| Item | Detail |
|---|---|
| Sponsor | GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) |
| Product | GFH276 – oral small‑molecule pan‑RAS (ON) inhibitor |
| Regulatory Progress | CTAs from CDE/NMPA (China); clinical trial notifications completed with TGA (Australia) |
| Scope | Multiple innovative combination therapies; first‑line and subsequent‑line settings |
| Target Population | Multiple major indications of RAS‑mutant solid tumors |
| Enrollment Status | Some trials already enrolling patients across multiple dose levels |
| Announcement Date | 4 Nov 2026 |
| Specific Study Designs / Indications | Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: GFH276, an oral small‑molecule pan‑RAS (ON) inhibitor — targeting the active, signaling‑competent state of RAS.
- Tri‑Complex Mechanism: Utilizes a CypA–GFH276–RAS tri‑complex mechanism of action, engaging cyclophilin A to lock the inhibitor onto its RAS target.
- Breadth of Coverage: Effectively inhibits most activated wild‑type and mutant RAS protein isoforms, covering the most common KRAS mutants (G12C, G12D, G12V) as well as NRAS and HRAS isoforms.
- Resistance Advantage: Preclinical studies show that, compared to KRAS inhibitors targeting the switch‑II pocket (SIIP), GFH276 holds the potential to overcome adaptive and acquired resistance limitations associated with existing therapies.
- Evidence Caveat: Resistance‑overcoming potential is based on preclinical data; clinical relevance has not yet been established.
Clinical Context & Unmet Need
RAS mutations are among the most frequent oncogenic drivers in human cancer, with KRAS G12C, G12D and G12V variants prevalent across lung, colorectal, and pancreatic malignancies. While first‑generation allele‑specific inhibitors validated RAS as drug‑targetable, their utility is constrained by adaptive feedback reactivation and acquired resistance — a gap that pan‑RAS (ON) inhibitors like GFH276 aim to address through broader isoform coverage and a distinct tri‑complex binding mode. Combination strategies from the first line onward reflect the field’s shift toward front‑loading RAS pathway suppression.
Market Impact & Outlook
- Clinical Velocity: With multiple CTAs secured in parallel across China and Australia and dose‑level enrollment already underway, GenFleet is executing an aggressive multi‑study strategy rather than a single‑trial path.
- First‑Line Ambition: Positioning GFH276 combinations in both first‑line and subsequent‑line settings targets the largest commercial opportunity in RAS‑mutant tumors, where treatment sequencing remains unsettled.
- Competitive Differentiation: The pan‑RAS (ON)/tri‑complex approach places GFH276 in direct competition with global SIIP‑based and other pan‑RAS programs, with preclinical resistance‑overcoming claims as its key differentiator.
- Dual‑Region Footprint: CTA approvals in China and Australia establish a foundation for multi‑regional oncology development supporting future global filing strategies.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development of GFH276, trial enrollment progress, combination strategies, and potential therapeutic benefits. Actual results may differ materially due to risks including clinical trial outcomes, safety findings, regulatory requirements, and competitive dynamics. GFH276 is investigational and has not been approved by any regulatory authority.-Fineline Info & Tech
